Therapy with bortezomib plus lenalidomide is tolerable in patients (pts) with relapsed/refractory mantle cell lymphoma (MCL): Interim results of CALGB 50501
- Citation:
- Ann Oncol vol 22 (221-222) abstr 436
- Meeting Instance:
- ICML 2011
- Year:
- 2011
- Type:
- Abstract
- Sub type:
- Poster General
- Funding:
- NCTN
- Endpoint:
- Primary
- Analysis:
- Preliminary
- Data Sharing:
- No-Data-Sharing
- Status:
- Presented/Published
- Citation Status:
- pub
- Note:
- Methodological:
- No
- Biospecimen:
- No
- SDC:
- No
- Parents:
- None
- Children:
- 2054
- Pharmas:
- Grants:
- Corr. Author:
- Authors:
- V. A. Morrison S. Jung J. Johnson J. Leonard B. Cheson
- Networks:
- Study
- CALGB-50101
- Multiple Studies, or Legacy Studies in Alliance Study:
- Phases:
- 3
- Keywords: